-transparent.png){kind=logo}
Chlorpropamide inhibited by 35 to 65% the increase in the urinary excretion of adenosine 3',5'-monophosphate (cyclic AMP) following a large dose (250 U) of parathyroid hormone (PTH) in normal subjects and patients with hypoparathyroidism and pseudohypoparathyroidism. By contrast, in normal subjects, the response of urinary cyclic AMP excretion to smaller amounts of PTH (15 and 30 U) was not decreased by chlorpropamide. Chlorpropamide did not decrease the phosphaturic response to any dose of PTH. The probable explanation for the discrepant effects of chlorpropamide on urinary cyclic AMP and phosphate excretions is that phosphaturia results from a minimal elevation of cyclic AMP and that chlorpropamide does not decrease cyclic AMP production to such a low level. Chlorpropamide decreased the accumulation of renal cyclic AMP in response to PTH in the parathyroidectomized rat, suggesting that this may be the mechanism of action for this drug in decreasing the urinary excretion of cyclic AMP in response to PTH in man. Tolazamide, another sulfonylurea, did not inhibit the elevation of urinary cyclic AMP excretion after PTH. Therefore, the sulfonylurea part of the molecule is probably not involved in the inhibition produced by chlorpropamide.
R Coulson, and
A M Moses
April 1991,
Ugeskrift for laeger,
R Coulson, and
A M Moses
July 1981,
Irish journal of medical science,
R Coulson, and
A M Moses
June 1982,
Ugeskrift for laeger,
R Coulson, and
A M Moses
January 1993,
Bone,
R Coulson, and
A M Moses
March 1984,
Nihon Naibunpi Gakkai zasshi,
R Coulson, and
A M Moses
February 1977,
The Journal of clinical endocrinology and metabolism,
R Coulson, and
A M Moses
April 1979,
Endocrinologia japonica,
R Coulson, and
A M Moses
October 1982,
The Tohoku journal of experimental medicine,
R Coulson, and
A M Moses
October 2011,
Indian journal of endocrinology and metabolism,
R Coulson, and
A M Moses
October 1957,
Helvetica medica acta,
